Spironolactone

螺内酯

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameSpironolactone
Drug Alias NameEspironolactona类甾醇螺旋内酯螺内脂Amiloride hydrochloride plus spironolactoneSpironolactonum +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMineralocorticoid receptor antagonists
TargetsMineralocorticoid receptor
Therapy Area/IndicationsRejection of renal transplantationIschemic StrokeTranssexualism +[41] 
Global Approved IndicationsEdemaAscitesHyperaldosteronism +[9] 
Approved Indications in ChinaEdemaHyperaldosteronismHypokalemia +[4] 
Original Approved Country/TerritoryCanada
Original Approved Date1959/12/31
Country/TerritoryBelgiumCanadaUnited States +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of Health Clinical Center (Cc)Institut National De La Santé Et De La Recherche Médicale, France U979University Of Pittsburgh Medical Center +[21] 
Inactive CompaniesInstituto Nacional De Cardiologia Ignacio ChavezInstituto Nacional De Ciencias Medicas Y Nutricion Salvador ZubiranCarelon Research +[21] 
Active IndicationsIschemic StrokeTranssexualismEdema +[27] 
Inactive IndicationsRejection of renal transplantationCritical IllnessVascular Calcification +[14] 

Other Information

ATC CodeC03DA01
Related LinksWikipediaDrugBankKEGG